Full-Time

Vaccine Account Director

Updated on 8/1/2026

Deadline 8/4/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$230.9k - $384.8k/yr

+ 25% bonus target + Share-based long-term incentive program

No H1B Sponsorship

Remote in USA + 1 more

More locations: New York, NY, USA

Remote

Must live in or relocate to the Northeast region or a commutable distance; approximately 50% overnight travel.

Category
Sales & Account Management (1)
Required Skills
Claude
Data Analysis

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • A bachelor's degree is required.
  • At least 12 years of pharmaceutical, biotechnology, or medical marketing, sales, or account management experience, including at least 5 years in a promoted position with demonstrated leadership experience across teams of varying size, location, and function.
  • People leadership experience is required, with strong experience in matrix environments.
  • A proven track record of leading teams to meet or exceed organizational goals is required.
  • Demonstrated negotiating and contracting experience is required.
  • Demonstrated ability to develop and motivate others and lead through change while delivering on business imperatives.
  • Demonstrated ability to build and lead a high-performance culture within a team.
  • Demonstrated ability to engage and influence high-level decision makers in large organized health systems, contracting entities, and other healthcare intermediaries.
  • Deep knowledge of the healthcare industry, quality measures, healthcare funding, and interactions among healthcare stakeholders.
  • Demonstrated prioritization, problem-solving, facilitation, and project management skills.
  • Strong ability to leverage data and insights to optimize decision-making.
  • Demonstrated financial acumen and understanding of healthcare market economics to guide account, contracting, and resource-allocation decisions.
  • Demonstrated ability to operate across brands and functions or business units on shared strategic issues.
  • Demonstrated ability to engage with senior leaders to provide performance updates and a strong grasp of business fundamentals.
  • Excellent oral and written communication skills and proficiency with Microsoft Office Suite, Claude, and Copilot.
  • Ability to live in or relocate to the region or a commutable distance from it.
  • Ability to travel overnight based on business requirements, approximately 50% or more.
  • Candidates must have permanent work authorization in the United States and be authorized to work for any employer.
Responsibilities
  • Provide leadership, prioritization, and management for a regional team of Vaccine Account Managers to achieve vaccine portfolio and product-access goals.
  • Lead regional Vaccine Account Managers to deliver targeted business outcomes that provide customer access to vaccines across complex customer channels.
  • Coach Vaccine Account Managers in cross-functional coordination, prioritization, strategic planning, project management, and capability development.
  • Ensure execution of the business-unit contracting strategy by Vaccine Account Managers and support customer engagement and negotiations as needed.
  • Ensure focused account-level business plans and develop regional business plans that consolidate regional priorities for organized customers.
  • Coach and support engagement with key customer stakeholders, including decision makers, influencers, health-system management, pharmacy and procurement leaders, clinical leaders, and system leadership.
  • Manage team performance and development by providing direction, prioritization, coaching, development feedback, field rides, business reviews, and performance objectives.
  • Objectively evaluate direct reports' performance using Pfizer performance and growth processes.
  • Lead and manage cross-functional projects with marketing, contracting, sales leadership, market access, strategy, enablement, and field medical teams.
  • Conduct colleague coaching, development, and performance management for direct reports in partnership with People Experience when needed.
  • Build relationships with key customers, stakeholders, and decision makers.
  • Assess local and broader customer and market dynamics that affect customers.
  • Identify and share lessons learned with U.S. Vaccine Leadership and cross-functional partners.
  • Model and drive productive collaboration among regions and customer-facing teams.
  • Align and collaborate with account-management leadership across Pfizer and ensure direct reports do the same.
  • Participate as a key member of the Vaccine Account Leadership Team to drive U.S. Vaccine and account-management goals.
  • Model and drive collaboration with Market Access, Government Affairs, Legal and Compliance, Field Medical, Commercial Effectiveness, and Brand Marketing.
  • Analyze organizational metrics, data, and market dynamics to prioritize opportunities, formulate business plans, and assess regional and individual performance.
  • Maintain knowledge of the healthcare industry landscape, including health-system use of artificial intelligence and health information technology, healthcare funding, quality measures, and stakeholder interdependencies.
  • Drive innovation and new approaches to meet business-unit objectives.
  • Manage deployment and execution of direct-report resources, including travel and entertainment budgets and approved materials.
  • Ensure account managers leverage planning resources to optimize business planning.
  • Reinforce training programs and platforms to develop Vaccine Account Manager capabilities.
  • Coach Vaccine Account Managers to maintain operating cadences and execution platforms, including account-plan updates, learning completion, customer reviews, and customer-facing activity targets.
Desired Qualifications
  • A master's degree and/or advanced training.
  • Strategy, marketing, operations, or other cross-functional experience.
  • Vaccines experience.
  • Experience engaging state and/or federal government stakeholders.
  • Experience as a leader of leaders.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Obesity asset MET097i targets 2028 launch to offset $17B–$18B patent cliff losses.
  • Oncology revenues grew 7% to $3.8B in Q1 2026, driven by Padcev and Lorbrena.
  • FDA approval for Padcev-Keytruda expands bladder cancer treatment to earlier disease stages.

What critics are saying

  • Eliquis, Ibrance, Xtandi, and Prevnar 13 lose exclusivity by 2028, dropping $17B revenue.
  • Sigvotatug vedotin failed Phase 3 for lung cancer, weakening Seagen's oncology pipeline de-risking.
  • Cash flow fell $700M short of covering dividends in 2025, pressuring the 7% yield.

What makes Pfizer unique

  • Pfizer leads with four marketed antibody-drug conjugates from its $43B Seagen acquisition.
  • The company offers a monthly GLP-1 obesity drug, berobenatide, from Metsera.
  • Patent-protected Padcev-Keytruda regimen is the first platinum-free option for bladder cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-4%
Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.